Nearly three-quarters of patients responded to treatment.
A new review points to low rates of genetic testing in patients with ovarian cancer.
One-third of patients had an additional lesion removed with use of pafolacianine sodium.
The combination produced durable responses in patients with high folate receptor alpha expression.
The 5-year overall survival rate was not improved by adjuvant chemotherapy.
The median progression-free survival was nearly 6 months longer in patients who underwent surgery.
For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.
Tisotumab vedotin is an investigational antibody-drug conjugate directed against tissue factor.
Investigators performed a final analysis of SOLO2 to investigate the effect of olaparib on overall survival in patients with ovarian cancer and a BRCA1/2 mutation.
Maintenance with a PARP inhibitor benefited all subsets of patients
There was a trend of different 5-year RFS among the groups, with the shortest among patients with MLH1-hypermethylated disease at 78.6% compared with 95.5% among patients with other causes of MMRd.
The study researchers reported that endometrial cancers with these somatic mutations have unfavorable pathologic features.
Researchers found that the benefit of adjuvant therapy differed depending on the status of peritoneal cytology in women with endometrial cancer.
Researchers sought to determine if LNG-IUD is effective and whether the addition of weight loss or metformin can further improve response in patients with EAC and EHA.
A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
The phase 3 trial evaluated the efficacy and safety of cemiplimab in women 18 years of age and older with recurrent or metastatic cervical cancer, including those with either squamous cell carcinoma or adenocarcinoma.
The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
Investigators evaluated the clinical benefits of sequential chemoradiation (SCRT), concurrent chemoradiation (CCRT), and radiation alone (RT) as postoperative adjuvant treatments in early-stage cervical cancer.
The cases were incidentally identified during a next-generation sequencing (NGS) analysis of matched normal and tumor tissue for a hospital-based prospective study.